Home Page / Science / Breakthrough in Rare Genetic Disease Treatment: Ibuprofen Shows Promise

11.11.202411.11.2024

Breakthrough in Rare Genetic Disease Treatment: Ibuprofen Shows Promise

A study in fruit flies has found that ibuprofen, a common over-the-counter pain reliever, may be a treatment for a rare genetic disease called MAN1B1-congenital disorder of glycosylation. The disease causes developmental delays, obesity, aggression, and distinctive facial features in children who inherit two faulty copies of the MAN1B1 gene. Preliminary results from a small trial of three children with the disease who took low-dose ibuprofen are “fairly positive.”

Forecast for 6 months: Expect more research and clinical trials to be conducted on the use of ibuprofen as a treatment for MAN1B1-congenital disorder of glycosylation, with potential FDA approval in the next 6 months.
Forecast for 1 year: By the end of the year, we may see the first large-scale clinical trials of ibuprofen as a treatment for MAN1B1-congenital disorder of glycosylation, with results that could lead to wider adoption of the treatment.
Forecast for 5 years: In the next 5 years, ibuprofen is likely to become a widely accepted treatment for MAN1B1-congenital disorder of glycosylation, with many more children benefiting from the treatment and potentially leading to a significant reduction in the disease’s prevalence.
Forecast for 10 years: By the end of the decade, we may see the development of new treatments for MAN1B1-congenital disorder of glycosylation that are more targeted and effective than ibuprofen, potentially leading to a cure for the disease.

Tags: development, DNA genome genetic, research